Can metformin prevent endothelial ischemia and reperfusion injury? The metformin-FMD trial.

Phase 4

Recruiting

• Conditions: ischemia and reperfusion injury; 10003216

• Registration Number: NL-OMON37620
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 26

Inclusion Criteria

- Age 30-50 years
- Written informed consent

Exclusion Criteria

- Smoking
- Hypertension (Psystole > 140mmHg, diastole > 90 mmHg)
- Hyperlipidaemia (fasting total cholesterol >5.5 mmol/L or random > 6.5 mmol/L)
- Diabetes Mellitus (fasting glucose > 7.0 mmol?L or random glucose > 11.0 mmol/L)
- History of any cardiovascular disease
- Concomitant chronic use of medication
- Renal dysfunction (MDRD < 60 ml/min)
- Professional athletes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in flow mediated dilation before and after 20 minutes of ischemia.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable.</p><br>